Cellectar CEO buys common stock and warrants
Cellectar Biosciences, Inc. director and Chief Executive Officer James V Caruso reported buying common stock and warrants in an open-market transaction.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Cellectar Biosciences, Inc. director and Chief Executive Officer James V Caruso reported buying common stock and warrants in an open-market transaction. He purchased 8,680 shares of common stock at $2.88 per share and 26,040 warrants at $0.01 per warrant, each relating to common stock at a $2.88 exercise price. Following these transactions, he directly holds 20,318 shares of common stock and 36,076 warrants. A footnote explains that the warrants are divided into tranches with terms of one, two, and five years from the date of stockholder approval.
Insider Trade Summary
Net Buyer: 34,720 shares
Net Buy
2 txns
Insider
CARUSO JAMES V
Role
Chief Executive Officer
Bought
34,720 shs ($25K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Warrants | 26,040 | $0.01 | $260.40 |
| Purchase | Common Stock | 8,680 | $2.88 | $25K |
Holdings After Transaction:
Warrants — 36,076 contracts (Direct);
Common Stock — 20,318 shares (Direct)
Footnotes (1)
- F1. Expiration dates are as follows: Tranche A shall have a one-year term from the date of stockholder approval; Tranche B shall have a two-year term from the date of stockholder approval; Tranche C shall have a five-year term from the date of stockholder approval.
Key Figures
Common shares purchased: 8,680 shares
Warrants purchased: 26,040 warrants
Common share purchase price: $2.88 per share
+4 more
7 metrics
Common shares purchased
8,680 shares
Open-market purchase at $2.88 per share on 2026-05-07
Warrants purchased
26,040 warrants
Open-market purchase at $0.01 per warrant on 2026-05-07
Common share purchase price
$2.88 per share
Price paid for common stock on 2026-05-07
Warrant exercise price
$2.88 per share
Exercise price for underlying common stock
Common shares after transaction
20,318 shares
Direct common stock holdings following reported trades
Warrants after transaction
36,076 warrants
Direct warrant holdings following reported trades
Net shares bought
34,720 units
Combined common stock and warrants bought; net-buy direction
Key Terms
open-market purchase, Warrants, underlying security, exercise price, +1 more
5 terms
open-market purchase financial
"transaction_action: "open-market purchase" for both common stock and warrants"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
Warrants financial
"security_title: "Warrants" with underlying security title "Common Stock""
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
underlying security financial
"underlying_security_title: "Common Stock" and underlying_security_shares: "26040.0000""
exercise price financial
"conversion_or_exercise_price: "2.8800" for the warrant transaction"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
tranche financial
"Tranche A shall have a one-year term from the date of stockholder approval"
A tranche is one slice of a larger financing or investment that is released, sold, or paid out in separate parts rather than all at once. Investors care because each slice can carry different risk, return and timing—like buying pieces of a cake where some slices are richer or come later—so the specific tranche you hold affects when you get paid and how much you might gain or lose.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Cellectar Biosciences (CLRB) report for its CEO?
Cellectar Biosciences reported that CEO and director James V Caruso made open-market purchases of common stock and warrants. He bought 8,680 common shares and 26,040 warrants on the same date, increasing his direct holdings in both securities.
What warrants did the Cellectar Biosciences (CLRB) CEO purchase and at what prices?
The CEO purchased 26,040 Cellectar Biosciences warrants at $0.01 per warrant. Each warrant relates to 26,040 underlying common shares with an exercise price of $2.88 per share, providing additional potential equity exposure if the warrants are exercised.
What are James V Caruso’s holdings after the CLRB insider transactions?
Following the reported transactions, James V Caruso directly holds 20,318 shares of Cellectar Biosciences common stock and 36,076 warrants. These figures combine his prior position with the newly purchased 8,680 shares and 26,040 warrants disclosed in the Form 4.
What do the warrant expiration terms mean in the Cellectar Biosciences (CLRB) filing?
A footnote explains the warrants are split into Tranche A, B, and C with one-year, two-year, and five-year terms, respectively, from the date of stockholder approval. This staggered structure defines how long each tranche can be exercised into common shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates